Table of Contents
ISRN Endocrinology
Volume 2011, Article ID 832642, 10 pages
http://dx.doi.org/10.5402/2011/832642
Research Article

Proteases in Plasma and Kidney of db/db Mice as Markers of Diabetes-Induced Nephropathy

1Department of Medical Biology, University of Tromsø, 9037 Tromsø, Norway
2Department of Pathology, Oslo University Hospital, Rikshospitalet, 0027 Oslo, Norway
3Kidney Section, Department of Internal Medicine, Oslo University Hospital, Rikshospitalet, 0027 Oslo, Norway
4Institute of Clinical Medicine, University of Tromsø, 9037 Tromsø, Norway
5Department of Nutrition, Institute for Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, 0316 Oslo, Norway

Received 26 April 2011; Accepted 31 May 2011

Academic Editors: Z. Canturk, Y. Combarnous, and V. Woo

Copyright © 2011 E. Hadler-Olsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Shamoon, H. Duffy, N. Fleischer et al., “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar
  2. H. J. Bangstad, R. Sterby, S. Rudberg, A. Hartmann, K. Brabrand, and K. F. Hanssen, “Kidney function and glomerulopathy over 8 years in young patients with type I (insulin-dependent) diabetes mellitus and microalbuminuria,” Diabetologia, vol. 45, no. 2, pp. 253–261, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Østerby, A. Hartmann, and H. J. Bangstad, “Structural changes in renal arterioles in type I diabetic patients,” Diabetologia, vol. 45, no. 4, pp. 542–549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. A. O. Phillips and R. Steadman, “Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury,” Histology and Histopathology, vol. 17, no. 1, pp. 247–252, 2002. View at Google Scholar · View at Scopus
  5. M. D. Vestra, “Role of mesangial expansion in the pathogenesis of diabetic nephropathy,” Journal of Nephrology, vol. 14, supplement 4, pp. S51–S57, 2001. View at Google Scholar
  6. S. M. Lee and A. Graham, “Early immunopathologic events in experimental diabetic nephropathy: a study in db/db mice,” Experimental and Molecular Pathology, vol. 33, no. 3, pp. 323–332, 1980. View at Google Scholar · View at Scopus
  7. D. Suzuki, M. Yagame, Y. Kim, H. Sakai, and M. Mauer, “Renal in situ hybridization studies of extracellular matrix related molecules in type 1 diabetes mellitus,” Nephron, vol. 92, no. 3, pp. 564–572, 2002. View at Google Scholar · View at Scopus
  8. E. C. Tsilibary, “Microvascular basement membranes in diabetes mellitus,” Journal of Pathology, vol. 200, no. 4, pp. 537–546, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. C. J. I. Raats, J. van den Born, and J. H. M. Berden, “Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria,” Kidney International, vol. 57, no. 2, pp. 385–400, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Liu, M. S. Razzaque, M. Cheng, and T. Taguchi, “The renal expression of heat shock protein 47 and collagens in acute and chronic experimental diabetes in rats,” Histochemical Journal, vol. 33, no. 11-12, pp. 621–628, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. M. P. Cohen, G. T. Lautenslager, and C. W. Shearman, “Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice,” Metabolism, vol. 50, no. 12, pp. 1435–1440, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Lenz, S. J. Elliot, and W. G. Stetler-Stevenson, “Matrix metalloproteinases in renal development and disease,” Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 574–581, 2000. View at Google Scholar · View at Scopus
  13. B. Turk, “Targeting proteases: successes, failures and future prospects,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 785–799, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. K. M. Thrailkill, R. Clay Bunn, and J. L. Fowlkes, “Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy,” Endocrine, vol. 35, no. 1, pp. 1–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. P. N. Furness, “Basement membrane synthesis and degradation,” The Journal of Pathology, vol. 183, no. 1, pp. 1–3, 1997. View at Google Scholar · View at Scopus
  16. K. Wu, S. Setty, S. M. Mauer et al., “Altered kidney matrix gene expression in early stages of experimental diabetes,” Acta Anatomica, vol. 158, no. 3, pp. 155–165, 1997. View at Google Scholar
  17. S. Y. Han, Y. H. Jee, K. H. Han et al., “An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2406–2416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. M. Catania, G. Chen, and A. R. Parrish, “Role of matrix metalloproteinases in renal pathophysiologies,” American Journal of Physiology, vol. 292, no. 3, pp. F905–F911, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. R. M. Mason and N. A. Wahab, “Extracellular matrix metabolism in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 14, no. 5, pp. 1358–1373, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Gharagozlian, K. Svennevig, H. J. Bangstad, J. O. Winberg, and S. O. Kolset, “Matrix metalloproteinases in subjects with type 1 diabetes,” BMC Clinical Pathology, vol. 9, no. 1, article 7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. K. M. Thrailkill, R. C. Bunn, C. S. Moreau et al., “Matrix metalloproteinase-2 dysregulation in type 1 diabetes,” Diabetes Care, vol. 30, no. 9, pp. 2321–2326, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. T. J. Allen, M. E. Cooper, and H. Y. Lan, “Use of genetic mouse models in the study of diabetic nephropathy,” Current Atherosclerosis Reports, vol. 6, no. 3, pp. 197–202, 2004. View at Google Scholar · View at Scopus
  23. K. Sharma, P. McCue, and S. R. Dunn, “Diabetic kidney disease in the db/db mouse,” American Journal of Physiology, vol. 284, no. 6, pp. F1138–F1144, 2003. View at Google Scholar · View at Scopus
  24. E. Hadler-Olsen, P. Kanapathippillai, E. Berg, G. Svineng, J. O. Winberg, and L. Uhlin-Hansen, “Gelatin in situ zymography on fixed, paraffin-embedded tissue: zinc and ethanol fixation preserve enzyme activity,” Journal of Histochemistry and Cytochemistry, vol. 58, no. 1, pp. 29–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Loennechen, B. Mathisen, J. Hansen et al., “Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4-independent manner,” Biochemical Pharmacology, vol. 66, no. 12, pp. 2341–2353, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Murphy and T. Crabbe, “Gelatinases A and B,” Methods in Enzymology, vol. 248, pp. 470–484, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. P. M. Rudd, T. S. Mattu, S. Masure et al., “Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin,” Biochemistry, vol. 38, no. 42, pp. 13937–13950, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Vartio and M. Baumann, “Human gelatinase/type IV procollagenase is a regular plasma component,” FEBS Letters, vol. 255, no. 2, pp. 285–289, 1989. View at Publisher · View at Google Scholar · View at Scopus
  29. S. V. McLennan, D. J. Kelly, A. J. Cox et al., “Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases,” Diabetologia, vol. 45, no. 2, pp. 268–275, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Dixon and C. Maric, “17β-estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-β protein expression and signaling,” American Journal of Physiology, vol. 293, no. 5, pp. F1678–F1690, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. X. M. Yao, S. D. Ye, Y. Chen et al., “Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression,” Diabetes, Obesity and Metabolism, vol. 11, no. 5, pp. 519–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. S. Signorelli, G. Malaponte, M. Libra et al., “Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease,” Vascular Medicine, vol. 10, no. 1, pp. 1–6, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. G. S. Butler and C. M. Overall, “Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics,” Biochemistry, vol. 48, no. 46, pp. 10830–10845, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Nagase and J. F. Woessner, “Matrix metalloproteinases,” Journal of Biological Chemistry, vol. 274, no. 31, pp. 21491–21494, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. C. R. Ban and S. M. Twigg, “Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers,” Vascular Health and Risk Management, vol. 4, no. 3, pp. 575–596, 2008. View at Google Scholar · View at Scopus
  36. S. W. Hong, M. Isono, S. Chen, M. C. Iglesias-de la Cruz, D. C. Han, and F. N. Ziyadeh, “Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the smad signaling pathway in the db/db mouse,” American Journal of Pathology, vol. 158, no. 5, pp. 1653–1663, 2001. View at Google Scholar · View at Scopus
  37. S. Chen, M. C. Iglesias-de la Cruz, B. Jim, S. W. Hong, M. Isono, and F. N. Ziyadeh, “Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice,” Biochemical and Biophysical Research Communications, vol. 300, no. 1, pp. 16–22, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. F. N. Ziyadeh, B. B. Hoffman, D. C. Han et al., “Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 8015–8020, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. H. J. Bangstad, R. Østerby, K. Dahl-Jørgensen, K. J. Berg, A. Hartmann, and K. F. Hanssen, “Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy,” Diabetologia, vol. 37, no. 5, pp. 483–490, 1994. View at Google Scholar · View at Scopus
  40. P. Fioretto, M. W. Steffes, D. E. R. Sutherland, F. C. Goetz, and M. Mauer, “Reversal of lesions of diabetic nephropathy after pancreas transplantation,” The New England Journal of Medicine, vol. 339, no. 2, pp. 69–75, 1998. View at Publisher · View at Google Scholar · View at Scopus